DE3776063D1 - Bryostatine. - Google Patents

Bryostatine.

Info

Publication number
DE3776063D1
DE3776063D1 DE8787306552T DE3776063T DE3776063D1 DE 3776063 D1 DE3776063 D1 DE 3776063D1 DE 8787306552 T DE8787306552 T DE 8787306552T DE 3776063 T DE3776063 T DE 3776063T DE 3776063 D1 DE3776063 D1 DE 3776063D1
Authority
DE
Germany
Prior art keywords
bryostatin
bryostatine
linneaeus
bryozoan
phylum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787306552T
Other languages
German (de)
English (en)
Inventor
George R Pettit
Cherry L Herald
Yoshiaki Kamano
John E Leet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Arizona State University ASU
Original Assignee
University of Arizona
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona State University ASU filed Critical University of Arizona
Application granted granted Critical
Publication of DE3776063D1 publication Critical patent/DE3776063D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE8787306552T 1986-07-28 1987-07-24 Bryostatine. Expired - Lifetime DE3776063D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same

Publications (1)

Publication Number Publication Date
DE3776063D1 true DE3776063D1 (en) 1992-02-27

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787306552T Expired - Lifetime DE3776063D1 (en) 1986-07-28 1987-07-24 Bryostatine.

Country Status (8)

Country Link
US (1) US4833257A (enExample)
EP (1) EP0264173B1 (enExample)
JP (1) JP2626889B2 (enExample)
AT (1) ATE71627T1 (enExample)
CA (1) CA1305476C (enExample)
DE (1) DE3776063D1 (enExample)
ES (1) ES2038664T3 (enExample)
GR (1) GR3004061T3 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
AU2337997A (en) * 1996-03-20 1997-10-10 Arizona Board Of Regents, The Method of treating cancer using c-26 modified bryostatin
JP2003515601A (ja) * 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US7402571B2 (en) * 2000-07-31 2008-07-22 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US6900339B2 (en) 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
WO2003099272A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CN1678304B (zh) * 2002-07-02 2012-06-27 布朗歇特洛克菲勒神经科学研究所 苔藓抑制素类化合物在制备用于活化PKC而增强sAPPα分泌和改善认知的药物中的应用
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
DK1651161T3 (da) 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1817020A4 (en) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
WO2007016202A1 (en) * 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
EP2452686A3 (en) * 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2762136A1 (en) 2006-07-28 2014-08-06 Blanchette Rockefeller Neurosciences, Institute Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
JP5872138B2 (ja) 2007-02-09 2016-03-01 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 虚血/卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
EP2185184A2 (en) * 2007-07-30 2010-05-19 HealOr Ltd. Pharmaceutical composition for treating wounds and related methods
MX2011007970A (es) * 2009-02-24 2011-10-19 Healor Ltd Agentes terapeuticos de visfatina para el tratamiento de acne y otras condiciones.
WO2011083481A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
WO2012006516A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
WO2012024630A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
EP2776018B1 (en) 2011-11-13 2021-08-25 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
CN105008342B (zh) * 2012-11-27 2018-10-19 阿菲欧斯公司 苔藓素组合物、其制备方法和用途
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
WO2016183252A1 (en) 2015-05-11 2016-11-17 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
US4833257A (en) 1989-05-23
JPS63183585A (ja) 1988-07-28
EP0264173A2 (en) 1988-04-20
EP0264173A3 (en) 1988-07-13
GR3004061T3 (enExample) 1993-03-31
CA1305476C (en) 1992-07-21
ATE71627T1 (de) 1992-02-15
ES2038664T3 (es) 1993-08-01
EP0264173B1 (en) 1992-01-15
JP2626889B2 (ja) 1997-07-02

Similar Documents

Publication Publication Date Title
DE3776063D1 (en) Bryostatine.
AU3264489A (en) 2-substituted-4-substituted-1,3-dioxalanes, synthesis and use thereof
EP0245518A4 (en) ISOFLAVONE DERIVATIVES, THEIR SALTS AND ONCOSTATIC AGENTS AND IMMUNOSUPPRESSANTS.
AU6307586A (en) Quinoline derivatives
AU1840788A (en) Compositions having hair growth stimulating activity
ES544752A0 (es) Un procedimiento para la preparacion de carbapenems.
AU7147287A (en) Five-membered N-heterocyclic derivatives of N'-substituted-N,N'-diacylhydrazines
AU600054B2 (en) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m- phenylene pgi2 derivatives
CA1265131C (en) ERYTHROMYCYLAMINE DERIVATIVES
WO1988003922A3 (en) Thiophenesulfonamide herbicides
IL107242A0 (en) Derivatives of benzeneborinic acid, preparation thereof and use thereof as synthetic intermediates
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
OA09221A (fr) "Synthèse asymétrique des dérivés de la furo (3, 4-c) pyridine".
AR241135A2 (es) "derivados de n-triazinil-n-sulfamoilurea herbicidamente activos y formulacion herbicida que los contiene".
PH24927A (en) Derivatives of substituted 1,2,3-thiadiazole-4-thiolate compounds
AU635400B2 (en) Intermediates for producing benzo(5,6)cycloheptapyridines
FI862861A0 (fi) Regelbar baeranordning.
LV5622A3 (lv) Panemiens aizvietotu 1,3,4,9-tetrahidropirano(3,4-b)indol-1-il-etikskabju vai to farmaceitiski saderigu salu iegusanai
LV5739B4 (lv) 1-Azatriciklo[7.2.03,8]undec-2-en-2-karbonskabes atvasinajumi
SU1417444A1 (ru) 2,4-Дифенил-3(4-ацетокси-4-метилгексин-2-ил)-3-азабицикло [3,3,1]нонан-9-он, проявляющий противовоспалительную активность

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee